Health Capital Helsinki
  • Home
  • Why Helsinki Metropolitan
  • About
  • News
  • Events
  • Opportunities
  • Careers
  • Contact
  • Search
  • Menu Menu
Keksi Agency / City of Helsinki
Jun 2, 2021

A new rapid test for coronavirus developed by researchers of the University of Helsinki

An antigen-based test could be used to analyse 500 samples per hour. The new test can also be used to quickly diagnose other respiratory infections.

Scientists at the University of Helsinki have developed a new antigen-based test for COVID-19.

The test is based on a phenomenon called ‘time-resolved Förster resonance energy transfer (TR-FRET). TR-FRET makes it possible to measure viral particles or the body’s own proteins by using ‘mix and read’-type tests on complex biological samples, such as serum or even whole blood. The new technique is capable of giving results in roughly 10 minutes.

“We demonstrated in our study that a technique based on the TR-FRET phenomenon can be used to diagnose SARS-CoV-2 infections in clinical specimens,” says Jussi Hepojoki, docent of virology and Academy of Finland research fellow at the University of Helsinki.

Accurate results and better safety for testers

In a recently completed study, the rapid test was able to diagnose a viral infection almost as accurately as PCR tests. Also, one of the major benefits of the new rapid test is its safety for testers. The virus becomes inactivated soon after it has been mixed in the test solution. 

“The theoretical capacity of the test is very high. According to our calculations, it would be possible to manually analyse as many as 500 samples per hour, with one person doing the testing and using a single testing device. Also, the cost of test reagents is fairly low,” Hepojoki says.

The new test format can also be used to rapidly check for other respiratory illnesses.

Read more

Photo: Keksi Agency Helsinki / City of Helsinki

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn

More news

Health Capital Helsinki

Close-up of unrecognizable woman using nasal sprayMarko Verch / Flickr

Researchers developed a potential key for future pandemics

Mar 31, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2023/03/Woman-nasal-spray_Flickr-1500x1000-1.jpg 1001 1500 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-03-31 12:47:332023-03-31 12:49:24Researchers developed a potential key for future pandemics
MVision AI software on a laptopMVision AI

Helsinki-based MVision AI raises EUR5.4M to speed up cancer treatment

Mar 27, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2023/03/MVision-image-w1200.jpg 675 1200 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-03-27 15:16:222023-03-29 14:41:55Helsinki-based MVision AI raises EUR5.4M to speed up cancer treatment
Two researchers in white coats walkingKeksi Agency via City of Helsinki

TILT Biotherapeutics, rising superstar of oncolytic immunotherapy

Mar 21, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2020/04/Keksi-Agency-via-City-of-Helsinki_communications.jpg 1653 2480 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-03-21 08:00:272023-03-29 15:04:22TILT Biotherapeutics, rising superstar of oncolytic immunotherapy
All news

Health Capital Helsinki

Helsinki Partners
Kasarmikatu 36
00130 HELSINKI
FINLAND

Privacy notice

Sign up to our newsletter

Subscribe

Follow us

  • twitter
  • linkedin
Health Capital Helsinki
Scroll to top

We use cookies to give you the best experience on our website.

Find out more and set your preferences settings.

Powered by  GDPR Cookie Compliance
How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential website cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are necessary to deliver the website as intended, refusing them will have impact how our site functions. You can always block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will prompt you to accept or refuse cookies every time you revisit our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Third party cookies

This website uses Twitter's and LinkedIn's cookies to help us improve our content and reach.

Please enable essential website cookies first so that we can save your preferences!

Privacy notice

You can read about how we use your data on our Privacy notice page.

Privacy notice